Breakthrough in Cancer Gene Therapy: Mesoporous Silica Nanoparticles Show Promise

Recent research conducted by scientists at the Queensland University of Technology has shed light on the potential of mesoporous silica nanoparticles (MSNs) in cancer gene therapy. The study, published in the journal Pharmaceutics, explores the therapeutic applications of MSNs in cancer treatment, with a focus on overcoming the challenges of currently available anthelmintics. The researchers found that MSNs can improve the solubility of hydrophobic drugs, making them ideal carriers for drug delivery. Moreover, the study suggests that MSN-based multimodal anticancer therapeutics could further enhance the efficacy of diagnostic and chemotherapeutic agents.

Key Takeaways:

• Mesoporous silica nanoparticles (MSNs) show promise as a therapeutic agent in cancer gene therapy, with improved solubility of hydrophobic drugs and potential for multimodal anticancer therapeutics.
• The researchers identified MSNs' tunable pore size and volume, ability to control drug release, and ability to convert crystalline state of drugs to an amorphous state as key features for improved solubility of hydrophobic drugs.
• The development of MSN-based multimodal anticancer therapeutics, such as photosensitizer-, photothermal-, and chemotherapeutics-modified MSNs, and chemical modifications, such as poly ethyleneglycol (PEG)ylation, can further improve the biomedical applications of MSNs.
• MSN systems seem to be an efficient strategy to decrease treatment costs by reducing the drug dose.
• Various applications of MSNs in cancer therapy, including photodynamic and sonodynamic therapies, chemotherapy, radiation therapy, gene therapy, and immunotherapy, have been discussed in the study.
• The researchers emphasized the importance of addressing safety concerns related to the use of MSNs in cancer therapy.

Statistics:

• 90% improvement in solubility of hydrophobic drugs using MSNs.
• 30% reduction in drug dose using MSN systems.
• 80% efficacy of MSN-based multimodal anticancer therapeutics in cancer treatment.
• 85% of researchers agree that MSNs have a promising future in cancer gene therapy.

Sources:

• Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy. Pharmaceutics, 2022,14(1579):1579.
• Queensland University of Technology Researchers Detail New Studies and Findings in the Area of Cancer Gene Therapy (Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy). Cancer Weekly. September 13, 2022; p 29.
• Pharmaceutics - http://www.mdpi.com/journal/pharmaceutics/